When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
AIDSPublished 1 May 2001
Alessandro Cozzi Lepri, Andrew Phillips, Antonella d’Arminio Monforte, Francesco Castelli, Andrea Antinori, Andrea De Luca
Citations107
SJR quartileQ1
SJR score1.21
SNIP0.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
There was no clear immunological or virological advantage in starting HAART at a CD4 cell count > 350 rather than at 200–350 × 106 cells/l, and the increase in CD4 cells restored by HAART is meaningful in that they are associated with reduced risk of disease/death.
Abstract
There was no clear immunological or virological advantage in starting HAART at a CD4 cell count > 350 rather than at 200--350 x 10(6) cells/l. The increase in CD4 cells restored by HAART is meaningful in that they are associated with reduced risk of disease/death.
Keywords
Immunology and MicrobiologyMedicine
AIDSA syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2,397 Citations1998Andrew Carr, Katherine Samaras +5 more
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance is a common complication of HIV protease inhibitors and diabetes mellitus is relatively uncommon.
Nature MedicineLatent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
2,141 Citations1999Diana Finzi, Joel N. Blankson +15 more
NatureIn vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
979 Citations1995Jon H. Condra, William A. Schleif +14 more
Five resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors, suggesting that com-bination therapy with multiple protease inhibition may not prevent loss of antiviral activity resulting from resistance selection.
The LancetClinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
933 Citations1999Bruno Ledergerber, Matthias Egger +10 more
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound.
The Journal of Experimental MedicineHIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function
864 Citations2000Victor Appay, Douglas F. Nixon +14 more
The majority of circulating CD8+ T cells specific for CMV and HIV antigens are functionally active with regards to the secretion of antiviral cytokines in response to antigen, although a subset of tetramer-staining cells was identified that secretes IFN-γ and MIP-1β but not TNF-α.
Nature MedicineOrdered accumulation of mutations in HIV protease confers resistance to ritonavir
766 Citations1996Akhteruzzaman Molla, Marina Korneyeva +15 more
Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitors ritonavir, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.
AIDSA syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
639 Citations2000Andrew Carr, J. Philip Miller +2 more
New England Journal of MedicinePersistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy
619 Citations1999Manohar R. Furtado, Duncan S. Callaway +6 more
Unless the quasi-steady state levels of HIV DNA and mRNA eventually disappear with longer periods of therapy, these findings suggest that HIV-1 infection cannot be eradicated with current treatments.
AIDSInsights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
554 Citations2000Antonella d’Arminio Monforte, Alessandro Cozzi‐Lepri +15 more
If the current HAART regimen caused no toxicity, less than 10% of naïve patients discontinue their firstHAART regimen because of failure after 1 year from starting therapy.
PubMedAIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
481 Citations1999Bruno Ledergerber, Matthias Egger +12 more
The data indicate that the risk of developing an OI for a person receiving potent antiretroviral therapy is highest during the initial months of therapy, and baseline CD4 cell count and immunologic and virologic response to treatment were strong predictors of disease progression in patients receiving potent therapy.
New England Journal of MedicineTime to Hit HIV, Early and Hard
431 Citations1995David D. Ho
Early treatment of asymptomatic human immunodeficiency virus type 1 (HIV-1) infection remains controversial.
AIDSHIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
424 Citations1999Steven G. Deeks, Frederick Hecht +5 more
Failure of potent protease inhibitor therapy to suppress HIV RNA levels below detectable levels is common in clinical practice, and can often be explained by their suboptimal use.
AIDSFactors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
177 Citations2000Sophie Grabar, Christian Pradier +9 more
In this study with large samples of patients, the use of saquinavir-hgc was associated with higher risk of virological failure at 12 months than were ritonavir and indinavir; no differences between protease inhibitors were found for clinical progression.
PubMedWhy is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.
160 Citations1999Stefano Bassetti, M Battegay +8 more
Multivariate logistic regression analysis indicated that patients with lower education, active intravenous drug users outside of a drug substitution program, and those who acquired HIV infection through IV drug use had a significantly higher risk of inadequate treatment.
New England Journal of MedicineDiscontinuation of Prophylaxis against<i>Mycobacterium avium</i>Complex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral Therapy
156 Citations2000Wafaa El‐Sadr, William J. Burman +9 more
Azithromycin prophylaxis can safely be withheld in HIV-infected patients whose CD4+ cell counts have increased to more than 100 cells per cubic millimeter in response to antiretroviral therapy.
BMJHIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion
102 Citations1994Alessandro Cozzi Lepri, Patrizio Pezzotti +3 more
There seems to be little evidence for appreciable differences in the natural course of HIV infection between men and women followed up for up to nine years after an accurately estimated date of seroconversion.
Journal of Clinical MicrobiologyClinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma
81 Citations1998Frederick S. Nolte, Jodi Boysza +3 more
The performance characteristics of an enhanced-sensitivity branched-DNA assay (bDNA) and a reverse transcription (RT)-PCR assay (RT-PCR) were compared in a molecular diagnostic laboratory and one non-B subtype was recognized in clinical specimens based on the ratio of values obtained with the two methods.
The Journal of Infectious DiseasesCD4 Lymphocyte Count as a Predictor of the Duration of Highly Active Antiretroviral Therapy–Induced Suppression of Human ImmunodeficiencyVirus Load
75 Citations1999Veronica Miller, Schlomo Staszewski +8 more
Lower baseline CD4 cell counts were associated with increased risk of viral rebound; however, this risk was significantly reduced in persons with low baseline CD 4 cell counts who experienced substantial increases in CD4 Cell counts during follow-up.
The LancetRisk of new AIDS diseases in people on triple therapy
40 Citations1999Veronica Miller, Schlomo Staszewski +4 more
The LancetHidden dangers of incompletely suppressive antiretroviral therapy
33 Citations1997Mark B. Feinberg
JAMAThe Case for Conservative Management of Early HIV Disease
28 Citations1998William J. Burman
Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidvudine-experienced patients: a randomized, double-blind, controlled trial.
JAMATreat HIV-1 Infection Like Other Infections—Treat It
22 Citations1998Bruce D. Walker
In this opinion, currently available data provide convincing arguments for initiation of therapy at the earliest possible juncture in persons who are not controlling viremia on their own.
AIDS Patient Care and STDsModels of Viral Kinetics and Drug Resistance in HIV-1 Infection
16 Citations1998Sebastian Bonhoeffer
The goal of this article is to illustrate to a readership with nonmathematical background how these models work, what key assumptions they make, and which questions they may help to answer.
PubMedWhen and where to start: guidelines for the initiation of antiretroviral therapy.
9 Citations2000Paul Volberding
Evidence suggests that a first-line, triple-nucleoside regimen may not be the best option, especially for people with more advanced disease, and some data indicate that PIs may exert beneficial effects not seen with other antiretrovirals.